Boston, MA (PressExposure) April 09, 2012 -- Since the introduction of second-generation DNA sequencing technologies in 2007, the cost of genome sequencing has been consistently declining by 33% per quarter, with the $1000 genome arriving in 2012 and the $100 genome not far off. As DNA sequencing increasingly becomes a commodity, biomedical research is rapidly evolving from a purely laboratory science to an information science in which the winners in the race to cure disease are likely to be those best able to collect, manage, analyze, and interpret data.
This presentation will provide an overview of the approach Dr. Quackenbush has been developing to deal with the challenge of personal genomic data, including integrative approaches to data analysis and the creation of data portals focused on addressing the most common use cases presented by different user constituencies. By effectively collecting genomic and clinical data and linking information available in the public domain, Dr. Quackenbush and his group have made significant advances in uncovering the cellular networks and pathways that underlie human disease and building predictive models of those networks that may help to direct therapies.
Attendees of this presentation will gain insight into some of the critical issues that must be addressed if one is to build a system that can effectively handle data in the age of genomic medicine and provide those data to the broad community of end users.
John Quackenbush received his PhD in 1990 in theoretical physics from UCLA working on string theory models. Following two years as a postdoctoral fellow in physics, Dr. Quackenbush applied for and received a Special Emphasis Research Career Award from the National Center for Human Genome Research to work on the Human Genome Project. He spent two years at the Salk Institute working on developing physical maps of human chromosome 11 and two years at Stanford University working on new laboratory and computational strategies for sequencing the Human Genome. In 1997 he joined the faculty of The Institute for Genomic Research (TIGR) where his focus began to shift to post-genomic applications with an emphasis on microarray analysis. Using a combination of laboratory and computational approaches, Dr. Quackenbush and his group developed analytical methods based on integration of data across domains to learn biological meaning from high-dimensional data. In 2005, he was appointed Professor of Biostatistics and Computational Biology and Professor of Cancer Biology at the Dana-Farber Cancer Institute (DFCI) and Professor of Computational Biology and Bioinformatics at the Harvard School of Public Health. Since that time, his work has increasingly focused on the analysis of human cancer using systems-based approaches to understanding and modeling biological problems. In 2009 he launched the Center for Cancer Computational Biology (CCCB) at the DFCI which provides broad-based bioinformatics support to the local research community using a collaborative consulting model.
GTC's 2nd Next Generation Sequencing Conference brings together leading experts across industry and academia to discuss the latest devices coming down the pipeline, discuss the endeavors of data analysis and management, learn about new discoveries on how sequencing has improved research, and share ideas with colleagues about the development of new techniques and protocols.
The conference is part of the Omics Evolution Summit, which includes 6 co-located conferences. Register for the entire summit and have access to the all of the following conferences:
2nd Genomic & Proteomic Drug Discovery Conference
2nd Epigenetics in Drug Discovery Conference
7th Protein Kinases in Drug Discovery Conference
3rd RNAi Research and Development Conference
Genome-wide Partnering and Deal Making Conference
Sign up for the pre-summit workshop on Clinical Sequencing on May 29th. This interactive workshop is dedicated to discussing emerging technologies, current and future trends of clinical sequencing, and the implementation of next generation sequencing in a CLIA environment.
For more information, please visit http://www.gtcbio.com